Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Cardea Bio is developing biology-based transistors for linking biology directly up to computers. These transistors leverage graphene and are designed to replace optical static observations with interactive live-streams of multi-omics signal analysis, representing a new life science observation paradigm according to the company, where multi-omics data-streams will be the new norm instead of most of […]
aiGENE is a US-based company developing a rapid, inexpensive, universal, pan-cancer screening test using DNA methylation technology licenced from The University of Queensland, Australia in 2020. The company’s approach uses an electrode based meter that generates a digital readout based on the amount of cancer DNA in a person’s blood. The “aiElectrode” is selectively sensitive […]
Founded in 2020, Asalyxa Bio is a spinout from the University of Michigan, focused on the rapid development of a new neutrophil-targeting drug platform. Neutrophils are immune cells that are involved in the systemic response to infection and injury. Asalyxa’s proprietary platform allows for the direct delivery of microparticles into neutrophils, making the platform suitable […]